fashion -WSS

fashion

author：Wikipedia 2025-09-29 20:17:33 - browse：44

Several amyloid plaques forming between neurons in a brain — Amyloid plaques forming between neurons. Adobe

The Food and Drug Administration on Thursday granted full approval to the first therapy for Alzheimer’s disease clearly shown to slow the cognitive decline associated with the disease — a milestone in treatment, even if the benefits are modest.

The drug, called Leqembi, was developed by Eisai, the Japanese pharmaceutical company, and sold in partnership with Biogen. It previously secured conditional approval in January. The FDA’s decision will broaden patient access to the drug under the Medicare program and is likely to boost sales, even as Leqembi’s benefits and safety risks continue to be a source of debate.

Leqembi’s full, or traditional, approval was supported by results of a large clinical trial in which the drug slowed the rate of cognitive and functional decline by 27% compared to a placebo. Leqembi also beat placebo on a series of secondary measures of Alzheimer’s, and it had a dramatic effect on clearing toxic brain plaques called beta-amyloid, which play a role in the progression of the disease.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： New details revealed about Purdue's marketing of OxyContin

entertainment

WSS

Clinical trials must include more disabled people

Clinical trials must include more disabled people

Lung cancer is America's deadliest cancer. Yet so few get screened

Congress needs to close a vaccine

ASCO Takeaways: Winners, snoozers, and the art of cancer care

Living with Hashimoto's and celiac disease, and med school, too

entertainment

fashion

hotspot

Hollywood unions extend contract negotiations for actors

Eli Lilly’s Zepbound improved liver scarring in mid

Duchenne breakthrough therapy leaves behind pioneering families

Finland to offer bird flu vaccine to select groups of people, a possible global first

United colonoscopy coverage change 'may cost lives,' doctors say

Finland to offer bird flu vaccine to select groups of people, a possible global first

Continuity nursing helped my family in our darkest PICU moments

As Maui death toll rises, number of missing remains unclear

Wildfire smoke exposes gaps in outdoor worker protections

Listen: Racing for gene therapy & a pioneering approval

focus

Evacuations in place as 3 wildfires burn in eastern Washington state

ASCO Takeaways: Winners, snoozers, and the art of cancer care

An outdated Medicare rule harms dementia patients with anxiety

For pregnant people, addiction treatment shouldn't mean a call to child protective services

STAT wants to know your pick for a great summer read or listen

Medicare Advantage's lean provider networks lead CMS complaints

entertainment

entertainment

explore

focus